Notice of AGM
June 29 2007 - 7:06AM
UK Regulatory
RNS Number:3223Z
VASTox plc
29 June 2007
VASTox plc
("VASTox" or "the Company")
ANNUAL REPORT AVAILABLE - NOTICE OF AGM
Oxford, UK, 29 June 2007 - VASTox plc (AIM: VOX), a leading UK biotechnology
company, today announces that its Annual Report and Accounts for the year ended
31 January 2007 ("Annual Report") will be available for at least one month, free
of charge, at the Company's offices being 91 Milton Park, Abingdon, Oxfordshire
OX14 4RY. Electronic copies are available on the Company's website,
www.vastox.com.
The AGM of VASTox will be held at the offices of Huntsworth Health plc, 8th
Floor, 26 Finsbury Square, London EC2A 1SF, on Thursday, 19 July 2007 at
09.30hrs.
- ends -
For more information please contact:
VASTox
Steven Lee, PhD, Chief Executive Officer Tel: +44 (0)1235 443951
Darren Millington, ACMA, Chief Financial Officer
Citigate Dewe Rogerson
Mark Swallow / David Dible / Valerie Auffray Tel: +44 (0)207 638 9571
Evolution Securities
Tim Worlledge / Bobbie Hilliam / Neil Elliot Tel: +44 (0)207 071 4300
About VASTox plc
VASTox is a leading UK biotechnology company that discovers and develops
proprietary new drugs. The Company's internal drug development programmes are
underpinned by its advanced chemistry and drug screening (chemical genomics)
technology platforms, which it also provides on a collaborative or
fee-for-service basis to the pharmaceutical industry.
VASTox has a broad range of drug discovery programmes in the clinical,
pre-clinical and discovery stages of development, which target serious diseases
with a high unmet medical need. These therapeutic areas include neuro-disorders
(neurodegenerative and neuromuscular), anti-infectives, ophthalmic diseases,
oncology and regenerative medicines.
VASTox's in-house drug development capabilities combine world-class expertise in
both medicinal and carbohydrate chemistry with high-volume, high-content
screening using its proprietary zebrafish and fruitfly technologies (chemical
genomics). These whole organism screens have the potential to dramatically
decrease the time and cost of drug discovery and development by delivering data
that are highly predictive of the efficacy and toxicity of potential drug
compounds in humans.
The company listed on the AIM market of the London Stock Exchange in October
2004 - symbol: VOX
Further information about the company is available at www.vastox.com
This document contains "forward-looking statements" within the meaning of the
U.S. Private Securities Litigation Reform Act of 1995. Forward-looking
statements can be identified by words such as "anticipates", "intends", "plans",
"seeks", "believes", "estimates", "expects" and similar references to future
periods, or by the inclusion of forecasts or projections.
Forward-looking statements are based on the Company's current expectations and
assumptions regarding our business, the economy and other future conditions.
Because forward-looking statements relate to the future, by their nature, they
are subject to inherent uncertainties, risks and changes in circumstances that
are difficult to predict. The Company's actual results may differ materially
from those contemplated by the forward-looking statements. The Company cautions
you therefore that you should not rely on any of these forward-looking
statements as statements of historical fact or as guarantees or assurances of
future performance. Important factors that could cause actual results to differ
materially from those in the forward-looking statements and regional, national,
global political, economic, business, competitive, market and regulatory
conditions.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NOASEIFEUSWSESM
Vox Valor Capital (LSE:VOX)
Historical Stock Chart
From Dec 2024 to Jan 2025
Vox Valor Capital (LSE:VOX)
Historical Stock Chart
From Jan 2024 to Jan 2025
